Program
brensocatib
Also written as “Brensocatib”, “Brensocatib 10 mg” and “Brensocatib 25 mg”.
Its studies are mostly in Bronchiectasis · Nasal Polyps · Hidradenitis Suppurativa · Cystic Fibrosis · Renal Insufficiency, led by 2 companies.
Drug pageBrensocatib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Insmedits history only | 151 open or running | phase 3since Oct 14, 2020 | Jul 11, 2017 | Nov 25, 2026phase 1 · NCT07859007 |
| AstraZenecaits history only | 20 open or running | phase 1since Nov 3, 2014 | Nov 3, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 3, 2014.
- Jul 11, 2017Insmed’s first study: phase 2 study in BronchiectasisNew to InsmedInsmed · NCT03218917 · 256 enrolled · United States, Australia, Belgium and more
- Jun 9, 2019Named brensocatibINNProposed as its International Nonproprietary Name in WHO's List 121
- Oct 14, 2020Phase 3 study in Non-Cystic Fibrosis BronchiectasisInsmed · NCT04594369 · 1,767 enrolled · United States, Argentina, Australia and more
- Oct 14, 2021Phase 2 study in Cystic FibrosisInsmed · NCT05090904 · 29 enrolled · United States
- Apr 26, 2022Phase 1 study in Healthy VolunteerInsmed · NCT05355935 · 48 enrolled · United States
- Aug 24, 2022Phase 1 study in Hepatic ImpairmentInsmed · NCT05517525 · 30 enrolled · United States
- Dec 7, 20222 phase 1 studiesInsmed · NCT05652257, NCT05673603
- Apr 12, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05826574 · 32 enrolled · United States
- Jun 22, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05927597 · 82 enrolled · United States
- Jul 19, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05965570 · 22 enrolled · United States
- Aug 22, 2023Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsInsmed · NCT06013241 · 288 enrolled · United States, Argentina, Australia and more
- Dec 12, 2023Phase 1 study in Healthy VolunteersInsmed · NCT06178783 · 20 enrolled · United States
- Mar 27, 2024Phase 1 study in Healthy ParticipantsInsmed · NCT06344728 · 24 enrolled · United States
- Nov 11, 2024Phase 2 study in Hidradenitis SuppurativaInsmed · NCT06685835 · 214 enrolled · United States, Australia, Bulgaria and more
- Sep 29, 2026Phase 1 study in Healthy VolunteersInsmed · NCT07859007 · 26 planned
Ahead
- Nov 25, 2026Primary completion: phase 1 study in Healthy VolunteersInsmed · NCT07859007
TargetBeta
“An orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), ”NCIt, by rule
“Dipeptidyl peptidase I inhibitor”ChEMBL 37, by rule
Other programs on CTSC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| verducatib | Boehringer Ingelheim | phase 3 | 21 |
| RSS0343 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07859007Healthy Volunteers | 1 | Not yet recruiting | Insmed | Nov 25, 2026 | 26 |
| NCT06685835Hidradenitis Suppurativa · United States, Australia, Bulgaria and more | 2 | Terminated | Insmed | Feb 12, 2026 | 214 |
| NCT06344728Healthy Participants · United States | 1 | Completed | Insmed | May 24, 2024 | 24 |
| NCT06178783Healthy Volunteers · United States | 1 | Completed | Insmed | Jan 4, 2024 | 20 |
| NCT06013241Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Australia and more | 2 | Completed | Insmed | Sep 30, 2025 | 288 |
| NCT05965570Healthy Volunteers · United States | 1 | Completed | Insmed | Sep 22, 2023 | 22 |
| NCT05927597Healthy Volunteers · United States | 1 | Completed | Insmed | Aug 1, 2019 | 82 |
| NCT05826574Healthy Volunteers · United States | 1 | Completed | Insmed | Jul 16, 2023 | 32 |
| NCT05673603Renal Insufficiency · United States | 1 | Completed | Insmed | Feb 14, 2023 | 28 |
| NCT05652257Healthy Volunteers · United States | 1 | Completed | Insmed | Sep 14, 2021 | 7 |
| NCT05517525Hepatic Impairment · United States | 1 | Completed | Insmed | Jun 1, 2023 | 30 |
| NCT05355935Healthy Volunteer · United States | 1 | Completed | Insmed | Oct 7, 2022 | 48 |
| NCT05090904Cystic Fibrosis · United States | 2 | Completed | Insmed | Nov 1, 2022 | 29 |
| NCT04594369Non-Cystic Fibrosis Bronchiectasis · United States, Argentina, Australia and more | 3 | Completed | Insmed | Oct 28, 2024 | 1,767 |
| NCT03218917Bronchiectasis · United States, Australia, Belgium and more | 2 | Completed | Insmed | Dec 12, 2019 | 256 |
| NCT02653872Healthy Subjects · United Kingdom | 1 | Completed | AstraZeneca | Apr 13, 2016 | 15 |
| NCT02303574Safety, Pharmacokinetics, Pharmacodynamics, Food Effect · United Kingdom | 1 | Completed | AstraZeneca | Aug 3, 2016 | 89 |
How it is read
Names in the registry
- “Brensocatib”, 10 entries
- “Brensocatib 10 mg”, 2 entries
- “Brensocatib 25 mg”, 2 entries
- “Brensocatib Oral Solution”, 1 entry
- “Brensocatib Oral Tablet”, 1 entry
Codes read as this program: AZD7986.
Conditions, from the studies’ own filings
- Bronchiectasis, 2 studies
- Nasal Polyps, 1 study
- Hidradenitis Suppurativa, 1 study
- Cystic Fibrosis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.